| IPF patients, n = 1218 | Using an anti-fibrotic, n = 703 | ||
---|---|---|---|---|
Characteristic: count, mean (SD) or Frequency (%) | No anti-fibrotic use (n = 487) | Anti-fibrotic use (n = 740) | Nintedanib (n = 312) | Pirfenidone (n = 391) |
Site-level Characteristics | ||||
 Region: South | 173 (36.2) | 332 (44.9) | 153 (49.0) | 161 (41.2) |
  Northeast | 96 (20.1) | 172 (23.2) | 73 (23.4) | 91 (23.3) |
  Midwest | 97 (20.3) | 154 (20.8) | 49 (15.7) | 99 (25.3) |
  West | 112 (23.4) | 82 (11.8) | 37 (11.9) | 40 (10.2) |
 Average UV index | 5.9 (1.1) | 5.9 (1.1) | 6.0 (1.1) | 5.9 (1.1) |
 Maximum UV index | 9.4 (1.0) | 9.4 (1.0) | 9.5 (1.1) | 9.4 (1.0) |
 Clinical trial experience – none | 59 (12.7) | 149 (20.1) | 71 (23.1) | 72 (18.9) |
  Pirfenidone only | 118 (25.5) | 185 (25.5) | 69 (22.5) | 105 (27.5) |
  Nintedanib only | 20 (4.3) | 22 (3.0) | 12 (3.9) | 8 (2.1) |
  Both pirfenidone and nintedanib | 265 (57.4) | 369 (50.1) | 155 (50.5) | 197 (51.6) |
 Participation in any trial (versus none) | 403 (87.2) | 576 (79.5) | 236 (76.9) | 310 (81.2) |